Avalo Therapeutics, Inc. AVTX
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Avalo Therapeutics, Inc. (AVTX) is a healthcare company listed in the US with a market value of about $449M. In the twelve months to September 30, 2026 it had revenue of $59000 and net income of -$89M, a net margin of -150259.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -61% a year, a 5-year average ROIC of -146%.
About Avalo Therapeutics
Avalo Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $1M in 2016 to $59000 in 2025, a decline of about 28.1% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 34094% over three years (dilution for shareholders). It spends 84888% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $59000 | $59000 | $441000 | $2M | $18M | $5M | $7M | $7M | $7M | $28M | $1M |
| Net income | -$89M | -$78M | -$35M | -$32M | -$42M | -$84M | -$64M | -$16M | -$40M | $12M | -$16M |
| Free cash flow | -$63M | — | -$49M | -$31M | -$27M | -$71M | -$41M | -$19M | -$4M | $13M | -$15M |
| EPS (diluted) | $-2.52 | $-5.84 | $-20.91 | $-113.58 | $-1063.00 | — | — | — | $-288.00 | $100.80 | $-448.80 |
| Net margin | -150259.3% | -132600.0% | -7965.8% | -1639.5% | -230.8% | -1563.1% | -947.9% | -238.1% | -569.9% | 42.7% | -1428.6% |
| ROIC | — | -69.0% | -40.4% | -234.7% | -275.3% | -111.1% | -221.1% | -57.3% | -77.0% | 39.4% | -496.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $34.80, 348% above the current price; targets range from $10.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-2.35 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Avalo Therapeutics pay a dividend?
Not currently.
Is Avalo Therapeutics a good stock to buy?
We do not give buy or sell advice. Avalo Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.